DossierENTITY

Lai Tsai-ta

Coverage of Lai Tsai-ta in the Nexus archive.

Earliest in view: Jun 6 · 00:00 UTCMost recent: Jun 6 · 00:00 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 6 · 00:00 UTCSCMP CHINA
Targeting US$610 billion longevity market, biotech firms race to reverse ageing
Biotech firms are targeting a US$610 billion longevity market to reverse aging by using AI to reprogram human cells, according to Beijing-based METiS TechBio CEO Lai Tsai-ta. The approach involves fixing errors in genetic code, such as DNA sequences, and potentially repairing immune cells like T cells to slow or reverse the aging process.
TECHNOLOGYJun 6 · 00:00 UTCSCMP WORLD
Targeting US$610 billion longevity market, biotech firms race to reverse ageing
Biotech firms are targeting a US$610 billion longevity market to reverse aging by reprogramming cellular errors using AI. METiS TechBio CEO Lai Tsai-ta compares aging to software bugs in DNA and suggests AI could repair immune cells like T cells to slow or reverse the process.